MA26967A1 - Derives de pyrimidine - Google Patents

Derives de pyrimidine

Info

Publication number
MA26967A1
MA26967A1 MA27173A MA27173A MA26967A1 MA 26967 A1 MA26967 A1 MA 26967A1 MA 27173 A MA27173 A MA 27173A MA 27173 A MA27173 A MA 27173A MA 26967 A1 MA26967 A1 MA 26967A1
Authority
MA
Morocco
Prior art keywords
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
MA27173A
Other languages
English (en)
Inventor
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26967A1 publication Critical patent/MA26967A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA27173A 2000-11-22 2003-05-22 Derives de pyrimidine MA26967A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00125529 2000-11-22

Publications (1)

Publication Number Publication Date
MA26967A1 true MA26967A1 (fr) 2004-12-20

Family

ID=8170446

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27173A MA26967A1 (fr) 2000-11-22 2003-05-22 Derives de pyrimidine

Country Status (30)

Country Link
US (1) US6787539B2 (fr)
EP (1) EP1339698A2 (fr)
JP (1) JP3993100B2 (fr)
KR (1) KR100571337B1 (fr)
CN (1) CN1309710C (fr)
AR (1) AR031486A1 (fr)
AU (2) AU2002227921B2 (fr)
BG (1) BG107840A (fr)
BR (1) BR0115480A (fr)
CA (1) CA2429570A1 (fr)
CZ (1) CZ20031666A3 (fr)
EC (1) ECSP034619A (fr)
GT (1) GT200100232A (fr)
HR (1) HRP20030362A2 (fr)
HU (1) HUP0303045A3 (fr)
IL (2) IL155705A0 (fr)
JO (1) JO2307B1 (fr)
MA (1) MA26967A1 (fr)
MX (1) MXPA03004453A (fr)
NO (1) NO324865B1 (fr)
NZ (1) NZ525555A (fr)
PA (1) PA8533501A1 (fr)
PE (1) PE20020760A1 (fr)
PL (1) PL366394A1 (fr)
RU (1) RU2284997C2 (fr)
SK (1) SK7612003A3 (fr)
UY (1) UY27034A1 (fr)
WO (1) WO2002042280A2 (fr)
YU (1) YU39503A (fr)
ZA (1) ZA200303517B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
WO2005047268A2 (fr) * 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Compositions de pyrimidine substituee et procedes d'utilisation associes
JP4501015B2 (ja) 2004-03-17 2010-07-14 味の素株式会社 アミノピリミジン化合物の製造方法
JP4613501B2 (ja) 2004-03-17 2011-01-19 味の素株式会社 ５−保護アミノピリミジン化合物の製造方法
US7280223B2 (en) * 2004-04-22 2007-10-09 Zygo Corporation Interferometry systems and methods of using interferometry systems
US7482350B2 (en) 2004-05-08 2009-01-27 Neurogen Corporation 4,5-disubstituted-2-aryl pyrimidines
CA2598762A1 (fr) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Comprimes presentant une dispersibilite de substance medicamenteuse amelioree
DE102005027150A1 (de) * 2005-03-12 2006-09-28 Bayer Healthcare Ag Pyrimidincarbonsäure-Derivate und ihre Verwendung
RU2279426C1 (ru) * 2005-03-15 2006-07-10 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) СПОСОБ ПОЛУЧЕНИЯ 2-(n-(1-АДАМАНТИЛ)ТИО)-4-(1-АДАМАНТИЛ)ОКСИ)-6-МЕТИЛПИРИМИДИНА
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
KR101032186B1 (ko) * 2008-12-31 2011-05-02 엘에스산전 주식회사 정격 미세 조정이 가능한 과전류 계전기
BR112012010253A8 (pt) 2009-10-30 2016-10-04 Janssen Pharmaceutica Nv compostos de pirimidina como moduladores do receptor delta opioide
BR112012010220A2 (pt) 2009-10-30 2021-02-23 Janssen Pharmaceutical N.V. piridinas fenóxi-substituídas como modulares do receptor opioide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57131771A (en) * 1981-02-10 1982-08-14 Mitsubishi Yuka Yakuhin Kk Novel pyrimidine derivative
FR2536071B1 (fr) * 1982-11-12 1986-07-11 Sanofi Sa Sels acides de 2-piperazinopyrimidine, procede pour leur preparation et compositions pharmaceutiques en contenant
EP0257102B1 (fr) 1986-02-24 1997-11-19 Mitsui Petrochemical Industries, Ltd. Agents therapeutiques de la neuropathie
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5734081A (en) * 1994-08-05 1998-03-31 Warner-Lambert Company Arylthio compounds
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4

Also Published As

Publication number Publication date
HRP20030362A2 (en) 2005-04-30
RU2003117481A (ru) 2005-02-20
ZA200303517B (en) 2004-08-10
HUP0303045A3 (en) 2004-03-29
JO2307B1 (en) 2005-09-12
CA2429570A1 (fr) 2002-05-30
RU2284997C2 (ru) 2006-10-10
PA8533501A1 (es) 2002-10-31
SK7612003A3 (en) 2004-05-04
PE20020760A1 (es) 2002-08-21
BG107840A (bg) 2004-01-30
NO324865B1 (no) 2007-12-17
NO20032291D0 (no) 2003-05-21
AR031486A1 (es) 2003-09-24
ECSP034619A (es) 2003-06-25
GT200100232A (es) 2002-07-04
JP3993100B2 (ja) 2007-10-17
IL155705A0 (en) 2003-11-23
CN1628103A (zh) 2005-06-15
HK1078079A1 (en) 2006-03-03
JP2004514673A (ja) 2004-05-20
MXPA03004453A (es) 2003-08-19
WO2002042280A2 (fr) 2002-05-30
CZ20031666A3 (cs) 2004-02-18
IL155705A (en) 2008-11-26
NO20032291L (no) 2003-05-21
YU39503A (sh) 2006-05-25
UY27034A1 (es) 2002-06-20
US6787539B2 (en) 2004-09-07
AU2002227921B2 (en) 2006-02-16
NZ525555A (en) 2004-10-29
KR20030060940A (ko) 2003-07-16
CN1309710C (zh) 2007-04-11
PL366394A1 (en) 2005-01-24
US20020099207A1 (en) 2002-07-25
HUP0303045A2 (hu) 2003-12-29
KR100571337B1 (ko) 2006-04-17
EP1339698A2 (fr) 2003-09-03
WO2002042280A3 (fr) 2002-08-22
BR0115480A (pt) 2003-10-21
AU2792102A (en) 2002-06-03

Similar Documents

Publication Publication Date Title
ATE372988T1 (de) Pyrimidin-derivate
DZ3439A1 (fr) Derives de 2-aminocarbonyl-9h-purine
MA26918A1 (fr) Derives de purine
HUS1500055I1 (hu) HIV-gátló pirimidinszármazékok
DE60119492D1 (de) Purinderivate
MA26799A1 (fr) Derives de purine
PT1303521E (pt) Derivados de tetra-hidro-heterocicloazepinil-pirimidina
FR2810318B1 (fr) Derives de diamano-phenothiazine
ATE334114T1 (de) Substituierte c-cyclohexylmethylamin-derivate
AR028602A1 (es) Derivados de pirrol
AR028282A1 (es) Derivados de aminofenil pirimidona
NO20032291D0 (no) Pyrimidinderivater
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
PT1351959E (pt) Novos derivados de pleuromutilina
ATE272045T1 (de) Substituierte 1-aminobutan-3-ol-derivate
PT1246791E (pt) Derivados de aminometilfenilciclo-hexanona
DE50112454D1 (de) Substituierte 5-amino-1-penten-3-ol-derivate
DK1246793T3 (da) Substituerede aminomethyl-phenyl-cyclohexanderivater